Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety and activity of the Avelumab in combination with
Carboplatin-Paclitaxel in advanced or recurrent endometrial cancer